LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >

YANGYI HE^1,2, DAVID SANCHEZ-LORENTE^3,4,5, MELISSA ACOSTA-PLASENCIA¹, MARC BOADA^3,4,5, ANGELA GUIRAO^3,4,5, RAMON M. MARRADES^4,5,6,7, LAUREANO MOLINS^3,4,5, ALFONS NAVARRO^1,4,5,*

BIOCELL, Vol.47, No.5, pp. 951-957, 2023, DOI:10.32604/biocell.2023.027718

Abstract Tumor-secreted extracellular vesicles (EVs) participate in the metastasis process through different mechanisms, including the preparation of the pre-metastatic niche to grant circulating tumor cells (CTCs) implantation and growth. The study of the metastasis process through the analysis of CTCs and tumor-derived EVs is difficult because of the dilution grade of these elements in peripheral blood. In early-stage lung cancer patients, the tumor-secreted products are even more diluted. An attractive strategy in surgical lung cancer patients is to purify them from a pulmonary tumor-draining vein where they are enriched. The information obtained from the analysis of EVs and CTCs purified from… More >

SANDRA STICKLER¹, BARBARA RATH¹, MAXIMILIAN HOCHMAIR², CLEMENS LANG³, LUKAS WEIGL⁴, GERHARD HAMILTON^1,*

Oncology Research, Vol.31, No.1, pp. 13-22, 2023, DOI:10.32604/or.2022.027281

Abstract Small cell lung cancer (SCLC) is frequently disseminated and has a dismal prognosis with survival times of approximately two years. This cancer responds well to initial chemotherapy but recurs within a short time as a globally chemoresistant tumor. Circulating tumor cells (CTCs) are held responsible for metastasis, the extremely high numbers of these cells in advanced SCLC allowed us to establish several permanent CTC cell lines. These CTCs are distinguished by the spontaneous formation of large spheroids, termed tumorospheres, in regular tissue culture. These contain quiescent and hypoxic cells in their interior and are associated with high chemoresistance compared to… More >

Debnath Bhattacharyya¹, Eali. Stephen Neal Joshua², N. Thirupathi Rao², Yung-cheol Byun^3,*

CMC-Computers, Materials & Continua, Vol.75, No.1, pp. 1447-1465, 2023, DOI:10.32604/cmc.2023.031878

Abstract Lung cancer is the leading cause of mortality in the world affecting both men and women equally. When a radiologist just focuses on the patient’s body, it increases the amount of strain on the radiologist and the likelihood of missing pathological information such as abnormalities are increased. One of the primary objectives of this research work is to develop computer-assisted diagnosis and detection of lung cancer. It also intends to make it easier for radiologists to identify and diagnose lung cancer accurately. The proposed strategy which was based on a unique image feature, took into consideration the spatial interaction of… More >

DIEGO HERNANDEZ^1,*, CHIH-YUAN CHENG^1,2, KARLA HERNANDEZ-VILLAFUERTE¹, MICHAEL SCHLANDER^1,2

Oncology Research, Vol.30, No.4, pp. 173-185, 2022, DOI:10.32604/or.2022.027262

Abstract Lung cancer is the most common cancer type worldwide and has the highest and second highest mortality rate for men and women respectively in Germany. Yet, the role of comorbid illnesses in lung cancer patient prognosis is still debated. We analyzed administrative claims data from one of the largest statutory health insurance (SHI) funds in Germany, covering close to 9 million people (11% of the national population); observation period was from 2005 to 2019. Lung cancer patients and their concomitant diseases were identified by ICD-10-GM codes. Comorbidities were classified according to the Charlson Comorbidity Index (CCI). Incidence, comorbidity prevalence and… More >

Ahmed A. Alsheikhy^1,*, Yahia F. Said¹, Tawfeeq Shawly²

Computer Systems Science and Engineering, Vol.46, No.1, pp. 799-817, 2023, DOI:10.32604/csse.2023.035269

Abstract Lung cancer is the leading cause of cancer-related death around the globe. The treatment and survival rates among lung cancer patients are significantly impacted by early diagnosis. Most diagnostic techniques can identify and classify only one type of lung cancer. It is crucial to close this gap with a system that detects all lung cancer types. This paper proposes an intelligent decision support system for this purpose. This system aims to support the quick and early detection and classification of all lung cancer types and subtypes to improve treatment and save lives. Its algorithm uses a Convolutional Neural Network (CNN)… More >

SITONG QIAN^1,2,#, YING FANG^1,#, CHENGYUN YAO^1,#, YONGSHENG WANG^3,#, ZHI ZHANG¹, XIAOHUA WANG¹, JIN GAO¹, YONG FENG¹, LEI SUN¹, RUNYUE ZOU², GUOREN ZHOU^1,*, JINJUN YE^1,*, RUIXUE XIA^4,*, HONGPING XIA^5,6,*

Oncology Research, Vol.30, No.2, pp. 53-64, 2022, DOI:10.32604/or.2022.026302

Abstract Previous studies have shown that PRDX5 and Nrf2 are antioxidant proteins related to abnormal reactive oxidative species (ROS). PRDX5 and Nrf2 play a critical role in the progression of inflammations and tumors. The combination of PRDX5 and Nrf2 was examined by Co-immunoprecipitation, western blotting and Immunohistochemistry. H₂O₂ was applied to affect the production of ROS and induced multi-resistant protein 1 (MRP1) expression in NSCLC cells. The zebrafish models mainly investigated the synergistic effects of PRDX5 and Nrf2 on lung cancer drug resistance under oxidative stress. We showed that PRDX5 and Nrf2 form a complex and significantly increase the NSCLC tissues… More >

P. S. Ramapraba^1,*, P. Epsiba², K. Umapathy³, E. Sivanantham⁴

Intelligent Automation & Soft Computing, Vol.36, No.2, pp. 2177-2189, 2023, DOI:10.32604/iasc.2023.032040

Abstract The classification of lung nodules is a challenging problem as the visual analysis of the nodules and non-nodules revealed homogenous textural patterns. In this work, an Auxiliary Classifier (AC)-Generative Adversarial Network (GAN) based Lung Cancer Classification (LCC) system is developed. The proposed AC-GAN-LCC system consists of three modules; preprocessing, Lungs Region Detection (LRD), and AC-GAN classification. A Wiener filter is employed in the preprocessing module to remove the Gaussian noise. In the LRD module, only the lung regions (left and right lungs) are detected using iterative thresholding and morphological operations. In order to extract the lung region only, flood filling… More >

YUANYUAN HUANG^#, HONGMEI WU^#, RUYUAN LIU, SONG JIN, WEILAI XIANG, CHANG YANG, LI XU, XIAONIAN ZHU^*

BIOCELL, Vol.47, No.3, pp. 445-454, 2023, DOI:10.32604/biocell.2023.025880

Abstract The tripartite motif (TRIMs) protein family has E3 ubiquitin ligase activity among most of its members. They participate in multiple cellular processes and signaling pathways in living organisms, including cell cycle, growth, and metabolism, and mediate chromatin modification, transcriptional regulation, post-translational modification, and cellular autophagy. Previous studies have confirmed that the TRIMs protein family is involved in the development of various cancers and correlated with the prognosis of tumor patients. Here we summarize the biological roles of the TRIMs protein family in cancers. More >

Jiajian Shi¹, Yuchen Chen^1,*, Chentai Peng¹, Linwu Kuang², Zitong Zhang¹, Yangkai Li^2,*, Kun Huang¹

Oncologie, Vol.24, No.4, pp. 613-648, 2022, DOI:10.32604/oncologie.2022.027545

Abstract The incidence and mortality of lung cancer rank top three of all cancers worldwide. Accounting for 85% of the total number of lung cancer, non-small cell lung cancer (NSCLC) is an important factor endangering human health. Recently, targeted therapies against driver mutations and epigenetic alterations have made encouraging advances that benefit NSCLC patients. Druggable driver mutations, which mainly occur in EGFR, KRAS, MET, HER2, ALK, ROS1, RET and BRAF, have been identified in more than a quarter of NSCLC patients. A series of highly selective mutant targeting inhibitors, such as EGFR tyrosine kinase inhibitors and KRAS inhibitors, have been well… More >